Are you over 18 years old?
This website requires you to be 18 years or older to enter our website and see the content.
A new experimental drug, retatrutide, is showing remarkable potential in weight loss, with some studies indicating it surpasses current popular medications like Ozempic and Zepbound. Developed by Eli Lilly, this "triple agonist" targets three key hormones involved in appetite and metabolism, offering a novel approach to weight management.
Retatrutide distinguishes itself by mimicking the action of three crucial gut hormones: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. While existing medications like Wegovy (semaglutide) and Zepbound (tirzepatide) target one or two of these hormones, retatrutide’s triple action is believed to contribute to its significant weight loss efficacy. GIP and GLP-1 help regulate appetite and metabolism by signaling the pancreas to release insulin, slowing digestion, and influencing appetite-regulating areas of the brain. Glucagon, on the other hand, helps the body break down fat for energy and speeds up metabolism. Retatrutide’s ability to activate all three pathways may offer a more potent effect on weight reduction.
Early clinical trials have yielded impressive results for retatrutide. In Phase 2 studies, participants using the highest doses (8 mg and 12 mg) experienced an average weight loss of approximately 23% to 24% of their starting body weight over 11 months. More recent Phase 3 trial data, focusing on individuals with obesity and knee osteoarthritis, showed an average weight loss of nearly 29% (about 71 pounds) after 68 weeks of treatment with the 12 mg dose. Beyond weight loss, these participants also reported significant reductions in knee pain and improvements in physical function.
While weight loss is a primary focus, retatrutide is also being explored for its potential to treat other health conditions. Similar to other GLP-1 based medications, it is being investigated for its impact on type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease, and cardiovascular risk reduction. The observed improvements in knee osteoarthritis pain and function suggest that retatrutide could offer a multifaceted approach to improving overall health.
Retatrutide is currently administered as a once-weekly injection in clinical trials, and this is the likely form it will take if approved. Eli Lilly, the manufacturer, is guiding the drug through its development process. Phase 3 trials are expected to conclude in early 2026, with a potential FDA submission and approval following, possibly in 2027. It’s important to note that counterfeit versions of retatrutide are being illegally sold, and the FDA warns against using unapproved or unregulated versions due to significant safety risks.
Thus far, the side effects reported with retatrutide appear consistent with those of other GLP-1 medications, primarily gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation. These effects are generally rated as mild to moderate and tend to be more noticeable when starting the medication. While serious side effects are rare, some participants in trials have experienced more significant adverse events, including increased heart rate, elevated liver enzymes, and kidney problems. A small percentage of participants in one trial discontinued treatment due to perceived excessive weight loss, highlighting the drug’s potent effects.
by 
